Case of Guillain-Barre in a Multiple Myeloma Patient after Treatment with Daratumumab and Bortezomib

Peripheral neuropathy is among the known adverse effects of bortezomib and daratumumab. Guillain-Barre (GBS) has been previously been reported as a rare adverse effect following bortezomib, but has yet to be reported after combination therapy of multiple myeloma (MM) with daratumumab and bortezomib.
Source: Archives of Physical Medicine and Rehabilitation - Category: Rehabilitation Authors: Tags: Research poster Source Type: research